DURECT Corp (DRRX)
$2.33
-0.01 (-0.43%)
| CAPS Rating |
|
|---|---|
| Open | $2.20 |
| Previous Close | $2.34 |
| Daily Range | $2.20 - $2.35 |
| 52-Week Range | $1.40 - $4.26 |
| Market Cap | $202.12M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 155,006 |
| Average Daily Volume | 194,000 |
DRRX
VS S&P 500 (SPY)
How do you think DRRX will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
DRRX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
DRRX News and Commentary
- 5 Top Stocks at Half Price – The Motley Fool
- The Real King of the Drug Pushers – The Motley Fool
- A Painful Letter from the FDA – The Motley Fool
- A Potentially Painless PDUFA Date – The Motley Fool
- DURECT's Intriguing Little Orphan – The Motley Fool
- 5 Deathbed Stocks – The Motley Fool
- Good News for Abuse-Resistant Drugs – The Motley Fool
- A Competitive Stab at King and Pain – The Motley Fool
- Pain Continues as Planned – The Motley Fool
- A Date With Pain – The Motley Fool
- The Extended Release That Wasn't – The Motley Fool
- Flamel's Frail, Fluctuating Future – The Motley Fool
- 4 Platform Drugmakers to Watch – The Motley Fool
- Direct Your Attention to DURECT – The Motley Fool
- RNAi Gets Pumped Up – The Motley Fool
- Pain-Free Payday for DURECT – The Motley Fool
- Another Free Quarter of Pain – The Motley Fool
Related News and Articles
- A Mostly Meaningless FDA Approval – The Motley Fool
RSS Headlines
Fool UK
